Ascendis Pharma A/S (NASDAQ:ASND – Free Report) – Analysts at Cantor Fitzgerald raised their FY2024 earnings per share (EPS) estimates for shares of Ascendis Pharma A/S in a note issued to investors on Tuesday, July 23rd. Cantor Fitzgerald analyst L. Watsek now expects that the biotechnology company will post earnings of ($4.00) per share for the year, up from their prior estimate of ($4.39). Cantor Fitzgerald has a “Overweight” rating and a $173.00 price objective on the stock. The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is ($5.57) per share.
Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last released its quarterly earnings results on Thursday, May 2nd. The biotechnology company reported ($2.48) EPS for the quarter, missing the consensus estimate of ($1.57) by ($0.91). Ascendis Pharma A/S had a negative net margin of 152.68% and a negative return on equity of 16,574.15%. The business had revenue of $103.11 million for the quarter, compared to analysts’ expectations of $85.72 million.
Get Our Latest Research Report on ASND
Ascendis Pharma A/S Stock Down 0.6 %
NASDAQ ASND opened at $134.01 on Thursday. Ascendis Pharma A/S has a 52 week low of $85.29 and a 52 week high of $161.00. The company has a 50-day moving average price of $132.35 and a 200-day moving average price of $139.28.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of ASND. Vestal Point Capital LP bought a new position in shares of Ascendis Pharma A/S during the 4th quarter valued at approximately $78,719,000. Price T Rowe Associates Inc. MD raised its holdings in Ascendis Pharma A/S by 23.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock valued at $269,374,000 after buying an additional 336,976 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in Ascendis Pharma A/S by 20.1% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,519,219 shares of the biotechnology company’s stock valued at $191,346,000 after buying an additional 254,749 shares during the period. Acadian Asset Management LLC raised its holdings in Ascendis Pharma A/S by 1,461.1% during the 1st quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock valued at $37,849,000 after buying an additional 234,446 shares during the period. Finally, Westfield Capital Management Co. LP raised its holdings in Ascendis Pharma A/S by 6.0% during the 4th quarter. Westfield Capital Management Co. LP now owns 4,030,634 shares of the biotechnology company’s stock valued at $507,658,000 after buying an additional 228,457 shares during the period.
About Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Featured Articles
- Five stocks we like better than Ascendis Pharma A/S
- 3 Stocks to Consider Buying in October
- Enphase Energy Stock: Growth in the Renewable Energy Transition
- Where Do I Find 52-Week Highs and Lows?
- ASML Stock Nearing Bottom: Is Now the Time to Buy?
- 3 Small Caps With Big Return Potential
- Earnings Season Sell-Off: Is This Tech Giant a Buy?
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.